verapamil has been researched along with Gaucher Disease in 4 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Gaucher Disease: An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, inhibition of L-type Ca(2+) channels, using either Diltiazem or Verapamil, has been reported to partially restore mutant glucocerebrosidase activity in cells from patients with Gaucher disease homozygous for the N370S or L444P alleles, as well as cells from patients with two other lysosomal storage diseases." | 3.75 | Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. ( Mahuran, D; Rigat, B, 2009) |
| "Diltiazem treatment (10 mg/kg/d) had essentially no effect on WT and V394L GCase protein or activity levels (<1." | 1.35 | In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models. ( Grabowski, GA; Liou, B; Quinn, B; Ran, H; Sun, Y; Xu, YH, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rigat, B | 1 |
| Mahuran, D | 1 |
| Sun, Y | 1 |
| Liou, B | 1 |
| Quinn, B | 1 |
| Ran, H | 1 |
| Xu, YH | 1 |
| Grabowski, GA | 1 |
| Ong, DS | 1 |
| Mu, TW | 1 |
| Palmer, AE | 1 |
| Kelly, JW | 1 |
| Aran, JM | 1 |
| Licht, T | 1 |
| Gottesman, MM | 1 |
| Pastan, I | 1 |
4 other studies available for verapamil and Gaucher Disease
| Article | Year |
|---|---|
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
Topics: Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Diltiazem; Dose-Response Relationship | 2009 |
In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Diltiazem; Disease Models, Animal; Fibr | 2009 |
Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis.
Topics: Amino Acid Substitution; Calcium; Calcium Channel Blockers; Diltiazem; Endoplasmic Reticulum; Gauche | 2010 |
Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy.
Topics: Animals; Anthracenes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; B | 1996 |